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Abstract
High-quality continuous medical education is essential to maintain excellence in health-care delivery,
upskilling professionals and improving patient outcomes. This is particularly relevant when addressing
rare disease groups, such as the spondyloarthritides, a group of heterogeneous inflammatory condi-
tions that affect joints and other organs, such as the skin, bowel and eye. Professional bodies, such
as the British Society for Rheumatology (BSR), are well placed to deliver this type of education. In
2020, the BSR ran a dedicated SpA course aimed at rheumatology health-care professionals wishing
to update their basic knowledge of SpA with a review of the latest advances in the field. Here, we
summarize the proceedings of the meeting and discuss the value of such an initiative.
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Introduction
The British Society for Rheumatology (BSR) is the UK’s
leading specialist medical society for rheumatology and
musculoskeletal professionals, with a wide membership
consisting of practising physicians, clinical and non-
clinical academics and allied health professionals. One
of the BSR remits is to support its members throughout
their careers, allowing them to progress, collaborate and
innovate so that they can deliver the best care for chil-
dren and adults with rheumatic musculoskeletal dis-
eases. To achieve this, BSR provides a wide range of
high-quality courses to support the ongoing professional
development of its membership.
In 2020, a group of physicians from the University of
Leeds proposed a dedicated BSR sponsored SpA
course. SpA is an umbrella term for a heterogeneous
group of conditions that includes axial spondyloarthritis
(axSpA), PsA, ReA and IBD-associated arthritis, which
share a number of clinical and genetic characteristics.
Despite a combined overall prevalence similar to that of
RA, the study of SpA was historically neglected, largely
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owing to the lack of reliable diagnostic and classification
criteria and the absence of efficacious therapies.
Furthermore, awareness of SpA, particularly in its axial
form, is variable and often poor among secondary and
primary care clinicians in the UK [1, 2]. The advent of
biologics and sensitive imaging techniques, such as US
and MRI, at the turn of the 21st century allowed for a
complete re-appraisal of these diseases, leading to sig-
nificant, rapidly evolving advances in the knowledge of
pathogenesis, diagnosis and treatment options. Yet, de-
spite these changes, SpA remains a niche area of inter-
est within rheumatology, with a limited number of
dedicated specialists and researchers and with a gen-
eral lack of specialist, tertiary clinics worldwide.
The 2020 BSR SpA Course offered rheumatology
health-care professionals the opportunity to update their
basic knowledge of SpA with a review of the latest
advances in the field. The course was conceived as a 1-
day combination of educational lectures, practical work-
shops and clinical case-based discussions facilitated by
leading experts. Attendance was restricted to 30 dele-
gates to allow for maximal interaction with the present-
ers and workshop participation. The purpose of this
review is to summarize the key presentations from the
2020 BSR SpA Course and reflect on the value of this
initiative based on the feedback provided by the attend-
ing delegates.
Lectures
Philip Helliwell: historical aspects
Professor Helliwell gave a brief summary of the recogni-
tion of SpA from the middle of the 20th century to the
present time. The SpA concept was developed in Leeds
by the rheumatologists Professor Verna Wright and Dr
John Moll [3]. Although laboratory tests, such as RF,
and X-ray imaging helped the synthesis and formulation
of their ideas, the concept was largely based on careful
clinical observation, and was contemporaneously sup-
ported by the discovery of HLA-B27 by Brewerton et al.
[4] in London. Wright and colleagues noted the key link-
ing feature to be inflammatory axial involvement and in-
cluded in the spondyloarthritides AS (as the key central
disorder), PsA, the arthritis associated with IBD, ReA
and Behcet’s syndrome (the last of these being removed
in a later publication). Professor Wright built a large co-
hort of patients in the Rheumatology Regional Centre in
Harrogate and in Leeds and passed this along to later
researchers, such as Professor Helliwell. From these
cohorts, refinements to classification were made. In
terms of PsA, the need for a new study became appar-
ent: the ClASsification Criteria for Psoriatic ARthritis
(CASPAR) classification study [5]. At the same time,
Professor Dennis McGonagle had the vision to see the
importance of the enthesis in the pathogenesis of SpA
and, together with Professor Michael Benjamin from
Cardiff, formulated the concept of the synovio-entheseal
complex [6]. Today, Leeds continues to lead research in
the pathogenesis and treatment of SpA, truly reflecting
its distinguished heritage.
Dennis McGonagle: pathogenesis and pathology in
spondyloarthritis
Professor McGonagle summarized the pathogenesis of
human SpA and explained how this was historically con-
ceptualized in relationship to early sacroiliitis and a role
of microbial triggers leading to an early synovitis with
joint erosion. Over two decades, it was firmly estab-
lished that the earliest lesion in axSpA was osteitis, typi-
cally in the subchondral bone adjacent to the
fibrocartilage of the sacroiliac joints [7]. It emerged that
the diffuse spinal involvement in SpA was also associ-
ated with diffuse peri-entheseal osteitis adjacent to the
fibrocartilage anchorage points of different entheses.
Likewise, enthesitis and adjacent osteitis formed the
common denominator for inflammation in the peripheral
skeleton and could be likened to SpA-like phenotypes,
including arthritis mutilans and SAPHO syndrome. Both
laboratory experimental studies and clinical trials have
brought into focus that disease in rodents can be bio-
mechanically driven [8] and that disease in humans can
be targeted successfully by anti-cytokine therapy, in-
cluding TNF, IL-17A and IL-23 targeting [9, 10], but the
last of these worked only in the peripheral SpA form.
Almost a decade ago, it was shown that the normal mu-
rine enthesis had a population of lymphocytes in the
enthesis soft tissue that appeared to drive disease, but
little was known about the enthesis in man.
The immunology of the normal human enthesis is now
beginning to emerge, and both the peri-entheseal soft
tissue adjacent to fibrocartilage and the underlying bone
anchorage points have resident populations of immune
cells in health. Both sites have resident myeloid cells
that are capable of TNF and IL-23 production [11]. The
sites also have resident ILC3 and gamma delta T cell
populations that do not express IL-17 transcript in basal
conditions but can be induced to do so. Of note, there
are two major populations of gamma delta T cells in the
spine, and one of these can produce IL-17A protein in
an IL-23-independent manner [12]. The human spinal
enthesis also has resident CD4þ T cells, and 2% of
these can make IL-17A and are classical Th17 cells.
Populations of CD8þ T cells are also present at the
enthesis, but with much lower inducible IL-17A produc-
tion, although TNF is readily inducible. Thus, it is begin-
ning to emerge that all of the cell types and cytokines
that are players in SpA in the experimental setting are
embedded in the normal enthesis. Studies of diseased
tissue are urgently needed to characterize both periph-
eral and axial entheses better, in order to begin deci-
phering the emergent differential efficacy of therapies in
these conditions. Another cardinal aspect of SpA patho-
genesis is the presence of either subclinical or clinical
gut involvement. Remarkably, many of the innate cell
types, including gamma delta T cells and Mucosal-asso-
ciated invariant T cells, might play important roles in
both gut and skeletal homeostasis, although how this
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gut–enthesis axis operates in SpA initiation and perpetu-
ation remains largely unknown.
Philip Helliwell: clinical presentation and diagnosis of
PsA
Professor Helliwell discussed the development of
CASPAR classification criteria for PsA and helpful tips in
diagnosing and distinguishing the condition. There is of-
ten confusion about the purpose of classification criteria,
which are often used in the clinic as diagnostic criteria.
In fact, in the case of the CASPAR classification criteria,
there is evidence that these criteria do work well as di-
agnostic criteria [5], the exceptions being in the very
early disease. It is also reassuring to know that the origi-
nal Moll and Wright criteria [3] are incorporated within
the new criteria. However, it might be time for a new set
of criteria for two reasons: problems with the stem (in-
flammatory musculoskeletal disease), and the advent of
new imaging, such as US.
In the clinic, there is usually no problem diagnosing
PsA (80% of patients have psoriasis at disease onset),
but difficulties in recognizing psoriasis and locating the
disease in hidden areas sometimes mislead the asses-
sor. Hallmark clinical features, such as dactylitis, enthe-
sitis and axial involvement, are helpful pointers. Areas of
uncertainty include DIP joint predominance and the pos-
sibility of nodal OA, chronic gout, which may present
with dactylitis, and seronegative RA. Key radiological
features, such as osteolysis and new bone formation,
are not early features, although US can help if enthesitis
is a marked feature. A key message was not to minimize
the importance of PsA in terms of disability and poor
quality of health; the patient may have oligoarthritis, a
few entheseal tender points and a patch of psoriasis,
but we know that the impact of the disease long term is
just as bad as with RA, meaning that early aggressive
treatment is recommended.
Helena Marzo-Ortega: clinical presentation and
diagnosis of axSpA
There are many challenges in the diagnosis of SpA, be-
cause no specific diagnostic criteria exist, which has led
to much confusion arising in recent years with the use
of classification criteria in clinical practice. Dr Marzo-
Ortega stressed that the diagnosis of axSpA should be
based on the recognition of clinical symptoms, with lab-
oratory and imaging features, taking into account any
possible differential diagnosis. Classification criteria, in
contrast, can be applied only once the diagnosis has
been made. The characteristics of the different classifi-
cation criteria were discussed (Fig. 1). The modified
New York criteria developed in 1984 [13], for example,
are highly specific for radiographic axSpA (r-axSpA),
also known as AS. The subsequently developed Amor
and ESSG criteria aim to classify the wider SpA group
and incorporate features such as extra-articular manifes-
tations. They allow for the recognition of an undifferenti-
ated SpA subgroup but do not differentiate between the
others (i.e. axSpA, PsA and peripheral SpA). The
Assessment of SpondyloArthritis (ASAS) criteria were
developed in 2009 [14], with the purpose of allowing the
classification of two homogeneous groups (predomi-
nantly axial and predominantly peripheral), in an attempt
to focus research efforts into these two main disease
subsets.
In axSpA, the ASAS criteria allow for disease classifi-
cation to be made according to the imaging arm or the
clinical arm. The imaging arm has higher sensitivity and
specificity because it is weighted towards imaging evi-
dence of sacroiliitis, identified either by structural
changes on plain radiographs (X-ray) or by the presence
of active bone marrow oedema representative of inflam-
mation on MRI. The criteria therefore allow for the identi-
fication of a non-radiographic subgroup, which can be
identified either by inflammatory changes on MRI or by
the presence of HLA-B27 and clinical features (clinical
arm). However, there are many shortcomings with X-ray
and MRI interpretation owing to the poor reliability of
structural changes with the former and the low specific-
ity of the latter. The recently published British Society of
Spondyloarthritis (BRITSpA) guidelines in the interpreta-
tion of MRI in axSpA [15] were discussed, and different
case scenarios were given to illustrate how to make a
clinical diagnosis of axSpA and the correct utilization of
available criteria.
Ai Lyn Tan: imaging in SpA
Dr Tan highlighted the two main areas of application for
imaging in SpA, namely in clinical practice and in the re-
search setting [16–18]. The clinical use of imaging in
SpA is supported by EULAR, who outlined its useful-
ness; in particular, the use of MRI and US [19]. The pre-
sentation focused on the research applications of MRI
and US in SpA owing to their significant contributions to
enhancing our understanding of the pathogenesis of
SpA [20, 21].
Dr Tan showcased how complementary data from his-
tology often improve the further understanding of the
imaging findings. For example, in Achilles enthesis, his-
tology helped explain the imaging observation of the
precise distribution of new bone formation or enthesop-
athy and erosive changes and showed that the respec-
tive differential locations are related to the trabecular
alignment within the calcaneum [22].
The digits are another good model for understanding
the involvement of the enthesis in SpA owing to their rel-
atively compact anatomy and close proximity with the
nails and skin, all of which can be affected in PsA [23,
24]. High-resolution MRI and US with histology demon-
strated that the pathological changes in the bones, ten-
dons and nails all share a common anatomical link with
various entheses that can therefore lead to diffuse in-
flammatory changes [25–29]. Functional enthesitis,
which results from abnormal friction according to a pul-
ley system, is well demonstrated in the extensor and
flexor tendons of the digits on both MRI and US, which
BSR Spondyloarthritis Course
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explains the diffuse swelling of dactylitis seen in PsA
[25, 28, 30–32].
Imaging has therefore contributed significantly to the
knowledge regarding the synovio-entheseal complex
[33]. Dr Tan used the analogy of the parable of the blind
people and an elephant to illustrate the appreciation of
the sites of pathology in SpA, from the key anatomy,
comprising the tendons/ligaments, synovium, joint cap-
sule and bone, to the initial description of the enthesis,
the interplay of these structures in the enthesis organ,
and culminating in their synergistic roles in the synovio-
entheseal complex [34–38] (Fig. 2).
Laura Coates: management of PsA
Dr Coates presented a brief update on the management
of PsA. She opened by summarizing the overarching
principles of treatment from the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) guidelines [39] and then talked through data
on currently available therapies. She highlighted recent
data on MTX, given the controversies over its evidence
in PsA, in addition to data for other conventional sys-
temic DMARDs. She discussed data for the currently
available biologic and targeted synthetic DMARDs, in-
cluding data from a new trial addressing the efficacy of
secukinumab in axial PsA: the first large randomized
controlled trial in axial PsA ever performed. She then
showed recent data from new therapies in development
for PsA, including bimekizumab, IL-23 inhibitors and se-
lective Janus Kinase1 inhibitors.
Dr Coates then went on to discuss studies that might
help to differentiate treatments in different domains of
PsA. She summarized data from head-to-head trials in
peripheral arthritis [40, 41] and enthesitis [42] before
summarizing the strengths and weaknesses of the cur-
rently available targeted therapies. Finally she discussed
the concept of treat to target in PsA, following the data
from the tight control of inflammation in early psoriatic
arthritis (TICOPA) trial [43] and international recommen-
dations on the implementation of treat to target [44].
She highlighted the impact this can have in routine clini-
cal practice and the availability of the GRAPPA app,
which includes a minimal disease activity calculator in
addition to a Psoriasis Area and Severity Index calcula-
tor, psoriatic arthritis impact of disease and psoriasis
epidemiology screening tool. This is free to download
and available in multiple languages.
Stefan Siebert: management of axSpA
Dr Siebert presented a brief update on the management
of axSpA. He started by highlighting that management
should be individualized and requires a multidisciplinary
approach, with the primary goal of maximizing health-
related quality of life. Key aspects of non-
pharmacological management are education, exercise,
physical therapy and smoking cessation. He covered
the range of pharmacological treatment options avail-
able for axSpA. He highlighted the efficacy of NSAIDs
for symptomatic improvement in axSpA and then dis-
cussed the controversy relating to the effect of high-
dose NSAIDs on radiographic progression, with early
studies suggesting a possible benefit, which was not
confirmed in the subsequent ENRADAS trial [45].
FIG. 1 Historical look at the classification criteria for spondyloarthritis
IBP: inflammatory back pain; LBP: low back pain.
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Dr Siebert then discussed the ASAS/EULAR and BSR
treatment recommendations for biologic DMARDs in
axSpA [46, 47]. He showed data indicating that both
TNF and IL-17A inhibition were associated with reduced
radiographic progression in the long term, with control of
disease activity being the key factor. He also described
the failure of IL-23 inhibition with both ustekinumab (p40)
[48] and risankizumab (p19) [49] in axSpA and reminded
the audience that SpA is characterized by inflammation at
multiple tissue sites with differential responses to cytokine
inhibitors [50]. He outlined factors, such as extra-articular
manifestations, co-morbidities and cost, that can help to
inform the choice of biologic in patients with axSpA in the
absence of head-to-head studies. The final part of the
talk described potential new therapies in development, in-
cluding Janus Kinase1 inhibitors and other strategies to
inhibit IL-17 signalling.
Workshops
Three workshops and a case-based facilitated discus-
sion were held.
David Pickles: skin and nails
The workshop began with a brief overview on the preva-
lence of nail disease in PsA [51, 52] and its impact on
patients’ experience of pain and functional impairment,
including a revision of the anatomy and physiology of
the nail bed and matrix and the different pathologies
that can arise from these structures. Delegates were in-
troduced to the Nail Psoriasis Severity Index (NAPSI), a
validated tool for the evaluation of nail psoriasis that is
reproducible, objective and simple to use. Delegates
learnt how to calculate the Psoriasis Area and Severity
Index (PASI), the most widely used tool for the measure-
ment of severity of skin psoriasis, whereby lesions are
appraised for the grade of erythema, desquamation, in-
duration and extent, in order to calculate the final score.
PsA is a very heterogeneous disease; therefore, dele-
gates were reminded of the need to quantify the differ-
ent manifestations of disease regularly, in order to
optimize treatment. Delegates were informed about vari-
ous smartphone apps to assist with this task.
Sayam Dubash: the spine and dactylitis
Spinal mobility measurements or axial clinimetrics in
SpA are performed in both clinical and research set-
tings. These were discussed in detail, including practical
methods and demonstration of measurements and cal-
culations using the different BASMI definitions: the linear
or 10-step, recommended by ASAS, and the original
two-step method. Dactylitis is the pathognomonic
FIG. 2 Evolution of the understanding of the synovio-entheseal complex
The blind people and the elephant analogy is used here to explain the conceptual understanding of the synovio-
entheseal complex over the past decades. The basic structures (i.e. the tendon/ligament or joint capsule and bone),
when put together, form the early description of the enthesis. The enthesis organ was later acknowledged owing to
the function of the enthesis in close proximity to other structures, such as the fibrocartilage. More recently, with fur-
ther advances in understanding of the pathogenesis of SpA, the interplay with the synovium that contributes synergis-
tically to the inflammatory process of enthesitis led to the term synovio-entheseal complex [37, 38]. Adapted from a
poem by John Godfrey Saxe (Cartoon originally copyrighted by the authors; G. Renee Guzlas, artist).
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peripheral clinical lesion in SpA. A summary of the path-
ophysiology of dactylitis followed by a clinical discussion
of differential diagnoses, including a hands-on experi-
ence with the dactylometer, was illustrated, leading to
working through a case study to calculate the Leeds
dactylitis index (LDI).
Claire Vandevelde: joints and enthesitis
The enthesitis workshop discussed the clinical difficul-
ties in the recognition of enthesitis because these
lesions are not generally associated with diffuse swelling
and can also be hard to differentiate from OA- or
FM-type pain. The role of imaging, and US in particular,
as a clinical adjunct for diagnosis facilitation was also
discussed. The ongoing difficulty in the evaluation of
enthesitis was recognized.
Cased-based discussions
A series of real-life cases were presented, focusing on
oligo-articular disease, axial involvement, co-morbidities
and treatment failures. Each presentation consisted of a
history, examination, laboratory tests and imaging, and
each section was followed by questions for the audi-
ence with input from the specialist presenters, making
the process interactive throughout. Before the meeting,
delegates were encouraged to present their own difficult
TABLE 1 Guidelines and recommendations for SpA in the last 5 years
Guidelines Disease Society Year Recommendations Reference
EULAR recommendations for the man-
agement of psoriatic arthritis with
pharmacological therapies: 2019
update
PsA EULAR 2019 Pharmacological
management
[55]
2018 EULAR recommendations for
physical activity in people with
inflammatory arthritis and
osteoarthritis
SpA, RA, OA EULAR 2018 Physical activity [56]
EULAR recommendations for the
health professional’s approach to
pain management in inflammatory
arthritis and osteoarthritis
AS, SpA, RA, OA EULAR 2018 Pain management [57]
BSR and BHPR guideline for the treat-
ment of axial spondyloarthritis
(including ankylosing spondylitis)
with biologics
axSpA BSR 2017 Pharmacological
management
[47]
2016 update of the ASAS–EULAR
management recommendations for
axial spondyloarthritis
axSpA ASAS–EULAR 2016 Non-pharmacological
and pharmacological
treatment
[46]
EULAR recommendations for cardio-
vascular disease risk management in
patients with RA and other forms of
inflammatory joint disorders: 2015/
2016 update
AS, PsA, RA EULAR 2015–2016 Cardiovascular disease
risk management
[58]
EULAR recommendations for the use
of imaging in the diagnosis and
management of spondyloarthritis in
clinical practice
SpA EULAR 2015 Imaging use [19]
EULAR recommendations for the man-
agement of psoriatic arthritis with
pharmacological therapies: 2015
update
PsA EULAR 2015 Pharmacological
management
[59]
Group for Research and Assessment
of Psoriasis and Psoriatic Arthritis
2015 treatment recommendations
for psoriatic arthritis
PsA GRAPPA 2015 Pharmacological
management
[39]
EULAR recommendations for patient
education for people with inflamma-
tory arthritis
AS, SpA, RA EULAR 2015 Patient education [60]
ASAS: Assessment of SpondyloArthritis; axSpA: axial spondyloarthritis; BSR: British Society for Rheumatology, BHPR:
British Health Professionals in Rheumatology; GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis.
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or interesting cases, and one such presentation was
made and discussed by the group.
Discussion
Continuing medical education refers to the need for
those working in medical disciplines to maintain compe-
tence and learn about new and developing areas of their
field to continue improving patient care. Offering health-
care professionals high-quality continuous education
leads to leveraging excellence in health-care perfor-
mance. This education can be delivered in multiple for-
mats, such as live conferences, written publications or
via online programmes or electronic media. The advan-
tages of investing in continuous education are many,
but chiefly aim for highly skilled professionals and better
patient outcomes. Nevertheless, there is no clear regula-
tion of how this continuing medical education should be
delivered, with the majority of provision being via the
scientific meetings of professional bodies or funded by
the pharmaceutical industry rather than through the
National Health Service or dedicated educational
courses.
The 2020 BSR SpA Course was put together to ad-
dress an unmet demand for clinical education across
the wide spectrum of SpA. The recently published
National Institute of Health and Care Excellence (NICE)
NG65 guideline for diagnosing and managing SpA [53]
and related quality standards [54] aim to raise aware-
ness of the features of SpA. These, together with other
guidelines and recommendations published in recent
years (Table 1), provide clear advice on what action to
take when people with signs and symptoms first present
in health-care settings and on the range of treatments
available. Nevertheless, a recent survey showed that
only half of rheumatology services in the UK have a
dedicated SpA clinic [61].
In the BSR course, one-third of attending delegates
were allied health professionals and primary care physi-
cians, with the rest being rheumatology clinicians (con-
sultants, trainees and specialty doctors), reflecting the
interest in SpA education outside secondary care.
Indeed, the majority of delegates (>90%) reported ‘im-
proving their knowledge’ as the main reason for attend-
ing the course, with 70% reporting having attended
other BSR educational meetings in the past. The overall
level of satisfaction with the course (individual speaker
quality, content) was very high (weighted average 4.3 of
5). One of the main comments was related to the value
of understanding how the experts incorporate research
or newly reported data into their clinical practice, with
94% of delegates reporting that attending the course
would change the way they work.
Conclusions
The 2020 BSR SpA Course brought together UK clinical
and academic experts in the SpA field with key presen-
tations on the latest developments in pathogenesis,
clinical challenges and treatment options in axSpA and
PsA and with excellent feedback from attending dele-
gates, who stated their willingness to attend similar
courses in the future. The challenge remains how best
to deliver and disseminate high-quality education in this
rapidly evolving field. Specialist organizations, such as
BSR or the more recently created British Society for
Spondyloarthritis (BRITSpA), are ideally positioned to
lead this challenge and educate UK-based rheumatology
health-care professionals in the complexities of SpA.
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